Document is current
Any future updates will be listed below
-
Authors
Bennabi, D.
Yrondi, A.
Charpeaud, T.
Genty, J.-B.
Destouches, S.
Lancrenon, S.
Allaili, N.
Bellivier, F.
Bougerol, T.
Camus, V.
Doumy, O.
Dorey, J.-M.
Haesebaert, F.
Holtzmann, J.
Lançon, C.
Lefebvre, M.
Moliere, F.
Nieto, I.
Rabu, C.
Richieri, R.
Schmitt, L.
Stephan, F.
Vaiva, G.
Walter, M.
Leboyer, M.
El-Hage, W.
Aouizerate, B.
Haffen, E.
Llorca, P.-M.
Courtet, P.
- License Information
-
More Information
Article History
Received: 7 August 2018
Accepted: 11 January 2019
First Online: 30 January 2019
Ethics approval and consent to participate
: Written informed consents were obtained from participating medical experts.
: Not Applicable.
: No financial support was received for this study and there are no potential conflicts of interest to declare. Regarding financial support unrelated to the present article, we disclose that NA has benefited from financial support for conferences and has been scientific responsible and experimenter for preclinical studies from Servier laboratories. BA has perceived honoraria to communicate at conferences from Laboratories AstraZeneca, Lundbeck and Janssen. VC has benefited from honoraria and financial support for conferences from Laboratories Otsuka, Novartis, Lundbeck, Servier, Janssen and has been experimenter for studies from Janssen and Lilly.TC has benefited from honoraria and financial support for conferences from Laboratories AstraZeneca, Janssen and Lundbeck and has been experimenter for studies from Janssen. PC has benefited from honoraria and financial support for conferences, training action and for participation in experts groups from Servier and Janssen. OD has benefited from honoraria and financial support for conferences from Lilly, AstraZeneca, Servier, Lundbeck and Janssen. J-MD has benefited from honoraria for conferences from Lundbeck. WE has benefited from honoraria and financial support for conferences, training action and for participation in experts groups from Lundbeck, Janssen, and Otsuka. FH has benefited from financial support for conferences, grant from BMS and AstraZeneca, training grant from Servier and a research grant from « Fonds de Recherche du Québec - Nature et Technologie (#200123) » and has been experimenter for studies from EH has benefited from honoraria and financial support for conferences, training action and for participation in experts groups from AstraZeneca, BMS, Euthérapie Servier, Janssen, Livanova, Lundbeck, Otsuka and has been experimenter for studies from Janssen. JH has benefited from honoraria and financial support for conferences from Lundbeck, Servier has been experimenter for studies from Janssen. CL has benefited from honoraria and financial support for training action from Lundbeck. P-ML has benefited from honoraria and financial support for conferences, training action and for participation in experts groups from Janssen, EISAI, Lundbeck, Otsuka, Allergan. FM has benefited from honoraria for conferences from Lundbeck, Otsuka. GV has benefited from honoraria and financial support for conferences, training action and for participation in experts groups from Janssen and Otsuka. AY has benefited from honoraria and financial support for conferences from Lundbeck, Janssen, AstraZeneca; for participation in experts groups from Lundbeck and has participated in reseach studies from Lundbeck.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
